

## PainChek completes \$10 million Placement

**Funds to accelerate growth opportunities including international expansion and development of new products**

### HIGHLIGHTS

- Commitments received for \$10m placement to professional and sophisticated investors at \$0.11 per share
- Offer saw strong demand from multiple existing and new offshore and Australian institutions and existing cornerstone shareholders
- PainChek to target international expansion of its adult dementia app into multiple markets
- PainChek to launch Home Care Dementia App in Australia by end of CY2020 and other markets in 2021
- PainChek Children's app targeting regulatory clearance in Australia and Europe in 2021
- Expansion of markets and new products follows PainChek's strong results in FY2020, which saw it achieve growth of more than 500% over its June 2019 results

PainChek® Ltd (ASX: PCK) ("PainChek®" or "the Company"), developer of the world's first smart phone-based pain assessment and monitoring application, is pleased to announce it has completed a \$10 million placement of new shares ("Placement") to accelerate its international expansion and to develop and launch new products.

PainChek completed the Placement of 90.9 million New Shares to professional and sophisticated investors under its existing 15% placement capacity under ASX Listing Rule 7.1. The Placement saw very strong support from multiple existing and new offshore and Australian institutional investors as well as existing cornerstone shareholders.

The issue price of A\$0.11 per share represents a:

- 15.4% discount to PainChek's last closing price of \$0.13 on 6 August 2020; and
- 14.1% discount to the 15-day VWAP of \$0.128.

PainChek CEO Philip Daffas said, "Such a substantial capital injection will allow us to launch in new markets sooner, building on our momentum in the past year which has seen us achieve growth of more than 500% in dementia beds at Australian residential aged care (RAC) facilities.

"We have continued to deliver strong sales growth during COVID-19. As a digital health technology, PainChek has the benefit of being implemented remotely through our e-learning and online training capability. The PainChek technology also allows pain assessments to be carried out at an appropriate distance, reducing the contact risk

between carers and their residents. The excellent traction we've achieved in the Australian RAC market shows the market need for our technology and gives us every confidence of the potential for PainChek overseas.

"With this additional funding, we will push forward with our plans to expand the PainChek dementia offering into aged care in our current and new geographies, while also developing on our significant opportunities in the home care, hospital and children's markets.

"We are very pleased to welcome a number of high-quality institutional investors onto the register and appreciate the ongoing support from our existing shareholders".

PainChek estimates a market revenue opportunity of more than A\$100m exists in the US and UK alone for its Adult App in aged care facilities, in addition to a further A\$900m for at home patients under a subscription model<sup>(1)</sup>.

Shares issued under the Placement will rank equally with existing shares on issue and are expected to be allotted on 17 August 2020. Bell Potter Securities Limited and Canaccord Genuity (Australia) Limited were Joint Lead Managers to the Placement.

This release has been authorized for release by CEO Philip Daffas.

**For more information:**

Ian Hobson  
Company Secretary, PainChek  
[ianhobson@bigpond.com](mailto:ianhobson@bigpond.com)  
+61 8 9388 8290

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

**About PainChek®**

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people living with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)

(1) See page 15 of ASX release 3 August 2020